Vaccinex secures $60 million to fund alzheimer's drug trial Dec 23, 2025 08:02AM
Vaccinex (VCNX) to present pepinemab data at ASCO 2025 May 27, 2025 08:46AM
Vaccinex (VCNX) to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy Apr 21, 2025 08:45AM
Vaccinex (VCNX) Receives Nasdaq Delisting Notice Dec 17, 2024 09:01AM
Vaccinex (VCNX) Provides Update on ActivMAb Platform: Multiple Project Deals and Presentation at SITC Nov 7, 2024 08:31AM


Nov 5, 2024 08:30AM Vaccinex (VCNX) Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
Oct 31, 2024 10:00AM Vaccinex (VCNX) Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab
Oct 16, 2024 04:47PM Vaccinex (VCNX) Files for 1.6M Share Offering by Selling Stockholders
Sep 18, 2024 08:32AM Vaccinex (VCNX) Receives $6.2M From Warrant Exercise
Aug 14, 2024 08:31AM Vaccinex (VCNX) Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab
Jul 31, 2024 09:00AM Vaccinex (VCNX) Reports Positive Data for SIGNAL-AD Phase 1b/2 trial
Jun 27, 2024 04:44PM Vaccinex (VCNX) Files for 490.5K Share Offering by Selling Stockholders